References
- Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–2221.
- Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 2007;7:911–924.
- Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 2011;7:1122–1144.
- Hinchcliffe EH, Sluder G. “It takes two to tango”: understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev 2001;15:1167–1181.
- Kramer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia 2002;16:767–775.
- Fukasawa K. Aberrant activation of cell cycle regulators, centrosome amplification, and mitotic defects. Horm Cancer 2011;2:104–112.
- Chng WJ, Ahmann GJ, Henderson K, et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006;107: 3669–3675.
- Dementyeva E, Nemec P, Kryukov F, et al. Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma. Leuk Res 2010;34:1007–1011.
- Kryukov F, Dementyeva E, Smetana J, et al. Association of aneuploidy category with centrosome amplification in multiple myeloma. Leuk Lymphoma 2011;52:2020–2022.
- Sevcikova S, Nemec P, Pour L, et al. Genomics in multiple myeloma research. Klin Onkol 2011;24:S34–S38.
- Nemec P, Zemanova Z, Kuglik P, et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2012;53: 920–927.
- Matsui S, Yamanaka T, Barlogie B, et al. Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma. Stat Med 2008;27:1106–1120.
- Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011;96: 87–95.
- Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.
- Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008;26: 4798–4805.
- Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–767.
- Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009;27:4197–4203.
- Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611–5622.
- Chng WJ, Braggio E, Mulligan G, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008;111:1603–1609.
- Dimopoulos MA, Barlogie B, Smith TL, et al. High serum lactate-dehydrogenase level as a marker for drug-resistance and short survival in multiple-myeloma. Ann Intern Med 1991;115:931–935.
- Tichy M, Maisnar V, Palicka V, et al. International Staging System required standardization of biochemical laboratory testing in multiple myeloma. Neoplasma 2006;53:492–494.
- Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 2002;29: 40–44.
- Tonon G, Anderson KC. Disentangling the myeloma web. Clin Cancer Res 2011;17:7210–7212.